19:01:23 (BST) 19:01:23 (BST)
CSE news on BEACONPHAR
2024-09-30: CB Free
BEACONPHAR: Please note that there will be no price limit today 30.09.2024 on the trading of the shares of the Company following its corporate declaration.
2024-09-30: Recommendation of Dividend
BEACONPHAR: The Board of Directors has recommended 20% Cash Dividend to General Shareholder and 10% Cash Dividend to Sponsor Shareholder and Directors for the year ended June 30, 2024. Date of AGM: 23.12.2024, Time: 11:00 AM,Venue: Digital Platform. Record Date: 27.10.2024. The Company has also reported EPS of Tk. 2.26, NAV per share of Tk. 26.37 and NOCFPS of Tk. (0.78) for the year ended June 30, 2024 as against Tk. 2.21, Tk. 25.72 and Tk.2.69 respectively for the year ended June 30, 2023.
2024-09-19: Board Meeting
BEACONPHAR: The Company has informed that the Board Meeting of the Company will be held on September 29, 2024 at 04:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2024.
2024-05-20: Change of Close Price
BEACONPHAR: Please note that the close price of the shares of BEACONPHAR has been reset at current market price prevailing in other exchange's Market. New close price of BEACONPHAR =Tk. 157.70.
2024-05-13: Un-audited Financial Statements
BEACONPHAR: (Quarter 3) As per un-audited financial statements of the Company, EPS was Tk. (0.95) for January-March 2024 as against Tk. (0.04) for January-March 2023; EPS was Tk. 2.38 for July 2023-March 2024 as against Tk. 2.57 for July 2022-March 2023. NOCFPS was Tk. (7.38) for July 2023-March 2024 as against Tk. 2.33 for July 2022-March 2023. NAV per share was Tk. 26.50 as on March 31, 2024 and Tk. 26.68 as on March 31, 2023.
2024-05-06: Board Meeting
BEACONPHAR: The Company has informed that the Board Meeting of the Company will be held on May 12, 2024 at 3:15 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2024.
2024-04-23: Cash Dividend Disbursement
BEACONPHAR: The Company has informed that it has disbursed the Cash Dividend for the year ended June 30, 2023 to the respective shareholders.
2024-01-31: Appointment of Company Secretary
BEACONPHAR: The Company has informed that the Board of Directors has appointed Mr. Md. Sahabuddin FCS as the Company Secretary of the Company with immediate effect.
2024-01-29: Un-audited HY A/Cs
BEACONPHAR: (Quarter 2) As per un-audited half yearly accounts of the company, EPS was Tk. 1.65 for October-December 2023 as against Tk. 1.61 for October-December 2022; EPS was Tk. 3.25 for July-December 2023 as against Tk. 2.60 for July-December 2022. NOCFPS was Tk. (2.34) for July-December 2023 as against Tk. 1.19 for July-December 2022. NAV per share was Tk. 27.38 as on December 31, 2023 and Tk. 26.76 as on December 31, 2022.
2024-01-25: Board Meeting
BEACONPHAR: The Company has informed that the Board Meeting of the Company will be held on January 28, 2024 at 4:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2023.
2023-11-16: Credit Rating
BEACONPHAR: Credit Rating Agency of Bangladesh Limited (CRAB) has announced the surveillance entity rating to Beacon Pharmaceuticals PLC. as ''AA3'' in the Long Term and ''ST-2'' in the short Term along with a stable outlook based on audited financial statements up to June 30, 2023, Bank liability position as on September 30, 2023 and other relevant quantitative as well as qualitative information up to the date of rating declaration.
2023-11-15: Record Date tomorrow (16.11.2023)
BEACONPHAR: Trading of the shares of Beacon Pharmaceuticals PLC will remain suspended on its record date i.e., 16.11.2023. Trading of the shares of the Company will resume on 19.11.2023.
2023-11-14: Un-audited Financial Statements
BEACONPHAR: (Quarter 1) As per the un-audited financial statements of the Company, EPS was Tk. 1.60 for July-September 2023 as against Tk. 0.99 for July-September 2022; NOCFPS was Tk. 0.66 for July-September 2023 as against Tk. 0.03 for July-September 2022. NAV per share was Tk. 27.32 as on September 30, 2023 and Tk. 26.72 as on September 30, 2022.
2023-11-13: Spot trade from tomorrow (14.11.2023)
BEACONPHAR: Trading of the shares of Beacon Pharmaceuticals PLC will be allowed only in the Spot Market from 14.11.2023 to 15.11.2023 as the record date of the Company is on 16.11.2023.
2023-11-08: Board Meeting
BEACONPHAR: Beacon Pharmaceuticals PLC has informed that the Board Meeting of the Company will be held on November 13, 2023 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2023.
2023-10-23: CB Free
BEACONPHAR: Please note that there will be no price limit today 23.10.2023 on the trading of the shares of the company following its corporate declaration. However, the floor price shall be applicable accordingly.
2023-10-23: Recommendation of Dividend
BEACONPHAR: The Board of Directors has recommended 16% cash dividend for the year ended on June 30, 2023. Date of AGM: 24.12.2023, Time: 11:00 AM, Venue: Digital Platform. Record date: 16.11.2023. The Company has also reported EPS of Tk. 2.21, NAV per share of Tk. 25.72 and NOCFPS of Tk. 2.69 for the year ended on June 30, 2023 as against Tk. 4.05, Tk. 25.73 and Tk. 4.68 respectively for the year ended June 30, 2022.
2023-10-16: Board Meeting
BEACONPHAR: Beacon Pharmaceuticals PLC has informed that the Board Meeting of the Company will be held on October 22, 2023 at 4:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2023.
2023-08-14: Appointment of Director
BEACONPHAR: Beacon Pharmaceuticals PLC has informed that the Board of Directors has appointed Mr. Ulfat Karim as the Director and Chief Operating Officer (COO) of the company.
2023-06-19: Appointment of Chief Financial Officer
BEACONPHAR: Beacon Pharmaceuticals PLC has informed that the Board of Directors of the Company has appointed Mr. Md. Jalal Uddin, FCA as Chief Financial Officer of the company with effect from June 06, 2023.
2023-05-11: Resignation of CFO
BEACONPHAR: Beacon Pharmaceuticals PLC has informed that Mr. Md. Abdul Haque Sarder, FCS, FCA, Director (Finance & Accounts) and CFO of the company resigned from his position with effect from May 09, 2023.
2023-05-02: Un-audited Financial Statements
BEACONPHAR: (Quarter 3) As per the un-audited financial statements of Beacon Pharmaceuticals PLC, EPS was Tk. (0.04) for January-March 2023 as against Tk. 0.99 for January-March 2022; EPS was Tk. 2.57 for July 2022-March 2023 as against Tk. 3.58 for July 2021-March 2022. NOCFPS was Tk. 2.33 for July 2022-March 2023 as against Tk. 1.16 for July 2021-March 2022. NAV per share was Tk. 26.68 as on March 31, 2023 and Tk. 25.26 as on March 31, 2022.
2023-04-18: Board Meeting
BEACONPHAR: Beacon Pharmaceuticals PLC has informed that the Board Meeting of the Company will be held on April 30, 2023 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2023.
2023-04-13: Name Change of the Company
BEACONPHAR: Chittagong Stock Exchange PLC (CSE) has approved the proposed name change of the Company. Accordingly, the name of the Company will be 'Beacon Pharmaceuticals PLC' instead of 'Beacon Pharmaceuticals Limited' with effect from April 16, 2023. Other things (except name) will remain unchanged.
2023-02-06: Cash Dividend Disbursement
BEACONPHAR: Beacon Pharmaceuticals Ltd. has informed that it has disbursed the cash dividend for the year ended June 30, 2022 to the respective shareholders.
2023-02-01: Un-audited HY A/Cs
BEACONPHAR: (Quarter 2) As per the unaudited half-yearly accounts of Beacon Pharmaceuticals Limited, EPS was Tk. 1.61 for October-December 2022 as against Tk. 1.07 for October-December 2021; EPS was Tk. 2.60 for July-December 2022 as against Tk. 2.59 for July-December 2021. NOCFPS was Tk. 1.19 for July-December 2022 as against Tk. (0.55) for July-December 2021. NAV per share was Tk. 26.76 as on December 31, 2022 and Tk. 24.27 as on December 31, 2021.
2023-01-25: Board Meeting
BEACONPHAR: Beacon Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on January 31, 2023 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2022.
2022-12-06: Credit Rating
BEACONPHAR: Credit Rating Agency of Bangladesh Limited (CRAB) has announced the surveillance entity rating to Beacon Pharmaceuticals Ltd. as ''A1'' in the long term and ''ST-3'' in the short term based on audited financial statements up to June 30, 2022; bank liability position as on September 30, 2022 and other relevant quantitative as well as qualitative information up to the date of rating declaration.
2022-11-16: Record Date tomorrow (17.11.2022)
BEACONPHAR: Trading of the shares of Beacon Pharmaceuticals Ltd. will remain suspended on its record date i.e., 17.11.2022. Trading of the shares of the Company will resume on 20.11.2022.
2022-11-15: Un-audited Financial Statements
BEACONPHAR: (Quarter 1) As per the un-audited financial statements of Beacon Pharmaceuticals Ltd., EPS was Tk. 0.99 for July-September 2022 as against Tk. 1.52 for July-September 2021; NOCFPS was Tk. 0.03 for July-September 2022 as against Tk. (0.65) for July-September 2021. NAV per share was Tk. 26.72 as on September 30, 2022 and Tk. 24.71 as on September 30, 2021.
2022-11-14: Spot trade from tomorrow (15.11.2022)
BEACONPHAR: Trading of the shares of Beacon Pharmaceuticals Ltd. will be allowed only in the Spot Market from 15.11.2022 to 16.11.2022 as the record date of the Company is on 17.11.2022.
2022-11-09: Board Meeting
BEACONPHAR: Beacon Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on November 14, 2022 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2022.
2022-10-26: CB Free
BEACONPHAR: Please note that there will be no price limit today 26.10.2022 on the trading of the shares of the company following its corporate declaration, however, as per the BSEC Order No. BSEC/CMRRCD/2001-07/39 dated July 28, 2022, the floor price shall be applicable accordingly.
2022-10-26: Recommendation of Dividend
BEACONPHAR: The Board of Directors has recommended 16% cash dividend for the year ended on June 30, 2022. Date of AGM: 27.12.2022, Time: 11:00 AM, Venue: Digital Platform. Record date: 17.11.2022. The Company has also reported EPS of Tk. 4.05, NAV per share of Tk. 25.73 and NOCFPS of Tk. 4.68 for the year ended on June 30, 2022 as against Tk. 3.74, Tk. 23.18 and Tk. 0.85 respectively for the same period of the previous year.
2022-10-20: Board Meeting
BEACONPHAR: Beacon Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on October 25, 2022 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2022.
2022-09-20: Query Response
BEACONPHAR: In response to a DSE query dated September 19, 2022, Beacon Pharmaceuticals Ltd. has informed that there is no undisclosed price sensitive information of the Company for recent unusual price hike and increase in volume of shares.
2022-09-08: CSE's Query Reply
BEACONPHAR: In response to CSE's query dated September 7, 2022 regarding the upward trend of its share price and volume, Beacon Pharmaceuticals Ltd. has informed that there is no undisclosed material decision/information relating to the Company's operation/profitability that might have impact on the trade of the shares of the Company.
2022-04-27: Un-audited Financial Statements
BEACONPHAR: (Quarter 3) As per the un-audited financial statements of Beacon Pharmaceuticals Ltd., EPS was Tk. 0.99 for January-March 2022 as against Tk. 2.01 for January-March 2021; EPS was Tk. 3.58 for July 2021-March 2022 as against Tk. 3.27 for July 2020-March 2021. NOCFPS was Tk. 1.16 for July 2021 -March 2022 as against Tk. (1.05) for July 2020 -March 2021. NAV per share was Tk. 25.26 as on March 31, 2022 and Tk. 22.71 as on March 31, 2021.
2022-04-20: Reschedule of Board Meeting
BEACONPHAR: Beacon Pharmaceuticals Ltd. has further informed that the Board Meeting of the Company will be held on April 26, 2022 at 2:15 PM instead of 2:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2022.
2022-04-20: Board Meeting
BEACONPHAR: Beacon Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on April 26, 2022 at 2:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2022.
2022-02-07: Category Change
BEACONPHAR: Beacon Pharmaceuticals Ltd. will be placed in 'A' category from existing 'B' category with effect from February 08, 2022 as the Company has reported disbursement of 15% cash dividend for the year ended June 30, 2021.
2022-02-07: Cash Dividend Disbursement
BEACONPHAR: Beacon Pharmaceuticals Ltd. has informed that it has disbursed the cash dividend for the year ended June 30, 2021 to the respective shareholders.
2022-01-30: Un-audited HY A/Cs
BEACONPHAR: (Quarter 2) As per un-audited half yearly accounts of Beacon Pharmaceuticals Ltd., EPS was Tk. 1.07 for October-December 2021 as against Tk. 1.01 for October-December 2020; EPS was Tk. 2.59 for July-December 2021 as against Tk. 1.26 for July-December 2020. NOCFPS was Tk. (0.55) for July-December 2021 as against Tk. (0.48) for July-December 2020. NAV per share was Tk. 24.27 as on December 31, 2021 and Tk. 20.71 as on December 31, 2020.
2022-01-23: Board Meeting
BEACONPHAR: Beacon Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on January 27, 2022 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2021.
2022-01-02: Credit Rating
BEACONPHAR: Credit Rating Agency of Bangladesh Limited (CRAB) has announced the Entity (surveillance) Rating of Beacon Pharmaceuticals Ltd. as ''A1'' based on audited financial statements up to June 30, 2021; bank liability position as on November 30, 2021 and other relevant quantitative as well as qualitative information up to the date of rating declaration.
2021-12-19: Record Date tomorrow (20.12.2021)
BEACONPHAR: Trading of the shares of Beacon Pharmaceuticals Ltd. will remain suspended on its record date i.e., 20.12.2021. Trading of the shares of the Company will resume on 21.12.2021.
2021-12-15: Un-audited Financial Statements
BEACONPHAR: (Quarter 1) As per the un-audited financial statements of Beacon Pharmaceuticals Ltd., EPS was Tk. 1.52 for July-September 2021 as against Tk. 0.25 for July-September 2020; NOCFPS was Tk. (0.65) for July-September 2021 as against Tk. (0.68) for July-September 2020. NAV per share was Tk. 24.71 as on September 30, 2021 and Tk. 20.29 as on September 30, 2020.
2021-12-14: Spot trade from tomorrow (15.12.2021)
BEACONPHAR: Trading of the shares of Beacon Pharmaceuticals Ltd. will be allowed only in the Spot Market from 15.12.2021 to 19.12.2021 as the record date of the Company is on 20.12.2021.
2021-12-13: BSEC's Time Extension
BEACONPHAR: BSEC has extended time to Beacon Pharmaceuticals Ltd. up to December 15, 2021 for submission of the first quarter financial statements for the quarter ended on September 30, 2021.
2021-12-12: Reschedule of Board Meeting
BEACONPHAR: Beacon Pharmaceuticals Ltd. has further informed that the Board Meeting of the Company will now be held on December 14, 2021 at 3:00 PM instead of December 12, 2021 to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2021.
2021-12-07: Board Meeting
BEACONPHAR: Beacon Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on December 12, 2021 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2021.
2021-11-29: CB Free
BEACONPHAR: Please note that there will be no price limit today 29.11.2021 on the trading of the shares of the company following its corporate declaration.
2021-11-29: Recommendation of Dividend
BEACONPHAR: The Board of Directors has recommended 15% cash dividend for the year ended on June 30, 2021. Date of AGM: 29.12.2021, Time: 11:00 AM, Venue: Digital Platform. Record date: 20.12.2021. The Company has also reported EPS of Tk. 3.74, NAV per share of Tk. 23.18 and NOCFPS of Tk. 0.85 for the year ended on June 30, 2021 as against Tk. 1.65, Tk. 20.04 and Tk. 1.26 respectively for the same period of the previous year.
2021-11-21: Board Meeting
BEACONPHAR: Beacon Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on November 28, 2021 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2021.
2021-11-18: BSEC's Time Extension
BEACONPHAR: BSEC has extended time to Beacon Pharmaceuticals Ltd. up to November 30, 2021 for submission of audited financial statements for the year ended on June 30, 2021 and first quarter financial statements for the period ended on September 30, 2021.
2021-08-12: Receiving GMP Certificate from Syrian Arab Republic
BEACONPHAR: Refer to their earlier news disseminated by CSE on 28.03.2021 regarding response to DSE's Query, Beacon Pharmaceuticals Ltd. has further informed that the Syrian Arab Republic has issued GMP (Good Manufacturing Practice) Certificate to the Company for the purpose of register the Beacon Pharmaceutical Ltd. for medicine.
2021-07-28: Query Response
BEACONPHAR: In response to a DSE query dated July 27, 2021, Beacon Pharmaceuticals Ltd. has informed that there is no undisclosed price sensitive information of the Company for recent unusual price hike and increase in volume of shares.
2021-05-19: Un-audited Financial Statements (Additional Information)
BEACONPHAR: (Quarter 3) Beacon Pharmaceuticals Ltd. has further informed that the turnover of the Company for the period July 2020 to March 2021 has been increased by 50% from the corresponding period of previous year. On the other hand, total Operating Expenses has been increased by only 9.60% from the corresponding period of previous year. Due to drastic increase of turnover and decrease of Operating expenses for the nine month period from July 2020 to March 2021 the EPS has been increased.
2021-05-19: Un-audited Financial Statements
BEACONPHAR: (Quarter 3) As per the un-audited financial statements of Beacon Pharmaceuticals Ltd., EPS was Tk. 2.01 for January-March 2021 as against Tk. 0.25 for January-March 2020; EPS was Tk. 3.27 for July 2020-March 2021 as against Tk. 0.55 for July 2019-March 2020. NOCFPS was Tk. (1.05) for July 2020 -March 2021 as against Tk. (1.18) for July 2019 -March 2020. NAV per share was Tk. 22.71 as on March 31, 2021 and Tk. 18.75 as on March 31, 2020.
2021-05-05: Board Meeting
BEACONPHAR: Beacon Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on May 18, 2021 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended on March 31, 2021.
2021-03-28: Cont-Response to DSE's Query
BEACONPHAR(cont):have the potential to increase exports to USD 10.00 million within one year which may have a positive financial impact of the Company. But no written agreement/deal has made yet. On the other hand worldwide COVID-19 situation is going down very roughly. In this situation we are not confirm regarding this deal before signing the agreement. We also assure you, after completion of the signing ceremony with the government of Syria we will inform you and other regulatory authorities on time."(end)
2021-03-28: Response to DSE's Query
BEACONPHAR: In response to a DSE query dated March 24, 2021 regarding clarification on recent news published in the newspaper, Beacon Pharmaceuticals Ltd. has informed that "We like to inform that a technical team of the government of Syria inspected the plant of Beacon Pharmaceuticals Limited on March 08, 2021. They expressed their satisfaction verbally on the Company's overall operations in drugs manufacturing. If the Syrian government agreed we may export USD 5.00 million worth of pharmaceuticals to Syria by December, 2021 and(cont)
2021-03-18: Query Response
BEACONPHAR: In response to a DSE query dated March 15, 2021, Beacon Pharmaceuticals Ltd. has informed that there is no undisclosed price sensitive information of the Company for recent unusual price hike and increase in volume of shares.
2021-01-31: Un-audited HY A/Cs
BEACONPHAR: (Quarter 2) As per un-audited half yearly accounts of Beacon Pharmaceuticals Ltd., EPS was Tk. 1.01 for October-December 2020 as against Tk. 0.12 for October-December 2019; EPS was Tk. 1.26 for July-December 2020 as against Tk. 0.30 for July-December 2019. NOCFPS was Tk. (0.48) for July-December 2020 as against Tk. (0.30) for July-December 2019. NAV per share was Tk. 20.70 as on December 31, 2020 and Tk. 20.04 as on June 30, 2020.
2021-01-25: Cash Dividend Disbursement
BEACONPHAR: Beacon Pharmaceuticals Ltd. has informed that it has disbursed the cash dividend warrants for the year ended on June 30, 2020 to the respective shareholders through courier service.
2021-01-25: Board Meeting
BEACONPHAR: Beacon Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on January 28, 2021 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2020.
2020-11-29: Credit Rating
BEACONPHAR: Credit Rating Agency of Bangladesh Limited (CRAB) has announced the Entity (surveillance) Rating of Beacon Pharmaceuticals Ltd. as "A2" based on audited financial statements up to June 30, 2020; bank liability position as on June 30, 2020 and other relevant quantitative as well as qualitative information up to the date of rating declaration.
2020-11-19: Record Date on 22.11.2020
BEACONPHAR: Trading of the shares of Beacon Pharmaceuticals Ltd. will remain suspended on its record date i.e., 22.11.2020. Trading of the shares of the Company will resume on 23.11.2020.
2020-11-17: Spot trade from tomorrow (18.11.2020)
BEACONPHAR: Trading of the shares of Beacon Pharmaceuticals Ltd. will be allowed only in the Spot Market from 18.11.2020 to 19.11.2020 as the record date of the Company is on 22.11.2020.
2020-11-16: Un-audited Financial Statements
BEACONPHAR: (Quarter 1) As per the un-audited financial statements of Beacon Pharmaceuticals Ltd., EPS was Tk. 0.25 for July-September 2020 as against Tk. 0.18 for July-September 2019; NOCFPS was Tk. (0.68) for July-September 2020 as against Tk. 0.18 for July-September 2019. NAV per share was Tk. 20.29 as on September 30, 2020 and Tk. 13.07 as on September 30, 2019.
2020-11-09: Board Meeting
BEACONPHAR: Beacon Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on November 15, 2020 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2020.
2020-10-28: CB Free
BEACONPHAR: Please note that there will be no price limit today 28.10.2020 on the trading of the shares of the Company following its corporate declaration, however, as per the BSEC Order No. BSEC/CMRRCD/2001-07/04 dated March 19, 2020, the floor price shall be applicable accordingly.
2020-10-28: Recommendation of Dividend
BEACONPHAR: The Board of Directors has recommended 6% cash dividend for the year ended on June 30, 2020. Date of AGM: 24.12.2020, Time: 11:00 AM, Venue: Digital Platform. Record date: 22.11.2020. The Company has also reported EPS of Tk. 1.65, NAV per share of Tk. 20.04 and NOCFPS of Tk. 1.26 for the year ended on June 30, 2020 as against Tk. 0.51, Tk. 12.90 and Tk. 0.95 respectively for the same period of the previous year.
2020-10-20: Board Meeting
BEACONPHAR: Beacon Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on October 27, 2020 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2020.
2020-07-16: Enquiry Committee formation by BSEC
BEACONPHAR: BSEC vide its Order No. BSEC/Surveillance/2020/930-104 dated July 16, 2020 has formed an enquiry committee to investigate into unusual movement of price and volume of shares of Beacon Pharmaceuticals Ltd. in the stock exchanges.
2020-06-28: Un-audited Financial Statements
BEACONPHAR: (Quarter 3) As per the un-audited financial statements of Beacon Pharmaceuticals Ltd., EPS was Tk. 0.25 for January-March 2020 as against Tk. 0.21 for January-March 2019; EPS was Tk. 0.55 for July 2019-March 2020 as against Tk. 0.56 for July 2018-March 2019. NOCFPS was Tk. (1.18) for July 2019-March 2020 as against Tk. 0.79 for July 2018-March 2019. NAV per share was Tk. 18.75 as on March 31, 2020 and Tk. 12.95 as on March 31, 2019.
2020-06-22: Board Meeting
BEACONPHAR: Beacon Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on June 25, 2020 at 2:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended on March 31, 2020.
2020-01-28: Un-audited HY A/Cs
BEACONPHAR: (Quarter 2) As per un-audited half yearly accounts of Beacon Pharmaceuticals Ltd., EPS was Tk. 0.12 for October-December 2019 as against Tk. 0.19 for October-December 2018; EPS was Tk. 0.30 for July-December 2019 as against Tk. 0.35 for July-December 2018. NOCFPS was Tk. (0.30) for July-December 2019 as against Tk. 0.03 for July-December 2018. NAV per share was Tk. 12.79 as on December 31, 2019 and Tk. 12.74 as on December 31, 2018.
2020-01-27: Cash Dividend Disbursement
BEACONPHAR: Beacon Pharmaceuticals Ltd. has informed that it has disbursed the cash dividend warrants for the year ended on June 30, 2019 to the respective shareholders through courier service.
2020-01-22: Board Meeting
BEACONPHAR: Beacon Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on January 27, 2020 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2019.
2019-11-21: CSE's Query Reply
BEACONPHAR: In response to a CSE query dated November 20, 2019 regarding the upward trend of its share price and volume, Beacon Pharmaceuticals Ltd. has informed that there is no undisclosed material decision/information relating to the Company's operation/profitability that might have impact on the trade of the shares of the Company.
2019-11-17: Credit Rating
BEACONPHAR: Credit Rating Agency of Bangladesh Limited (CRAB) has announced the Entity (surveillance) Rating of Beacon Pharmaceuticals Ltd. as "A3" based on audited financial statements up to June 30, 2019; bank liability position as on October 31, 2019 and other relevant quantitative as well as qualitative information up to the date of rating declaration.
2019-11-14: Record Date on 17.11.2019
BEACONPHAR: Trading of the shares of Beacon Pharmaceuticals Ltd. will remain suspended on its record date i.e., 17.11.2019. Trading of the shares of the Company will resume on 18.11.2019.
2019-11-14: Un-audited Financial Statements
BEACONPHAR: (Quarter 1) As per the un-audited financial statements of Beacon Pharmaceuticals Ltd., EPS was Tk. 0.18 for July-September 2019 as against Tk. 0.16 for July-September 2018; NOCFPS was Tk. 0.18 for July-September 2019 as against Tk. (0.11) for July-September 2018. NAV per share was Tk. 13.07 as on September 30, 2019 and Tk. 13.15 as on June 30, 2019.
2019-11-12: Spot trade from tomorrow (13.11.2019)
BEACONPHAR: Trading of the shares of Beacon Pharmaceuticals Ltd. will be allowed only in the Spot Market from 13.11.2019 to 14.11.2019 as the record date of the Company is on 17.11.2019.
2019-11-06: Board Meeting
BEACONPHAR: Beacon Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on November 13, 2019 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2019.
2019-11-03: Land Purchase
BEACONPHAR: Beacon Pharmaceuticals Ltd. has informed that the Board of Directors has decided to purchase a piece of vacant land measuring 73.00 decimal adjacent to Beacon's Factory premises at kathali, Bhaluka, Mymensingh valued of which amounting to Tk. 1,05,64,000.00 only.
2019-10-27: CB Free
BEACONPHAR: Please note that there will be no price limit today 27 October 2019 on the trading of shares of the Company following its corporate disclosure.
2019-10-27: Recommendation of Dividend
BEACONPHAR: The Board of Directors has recommended 5% cash dividend for the year ended on June 30, 2019. Date of AGM: 24.12.2019, Time: 11:00 AM, Venue: Registered Office at Kathali, Bhaluka, Mymensingh (Factory Premises). Record date: 17.11.2019. The Company has also reported EPS of Tk. 0.51, NAV per share of Tk. 12.90 and NOCFPS of Tk. 0.95 for the year ended on June 30, 2019 as against Tk. 0.55, Tk. 12.99 and Tk. 1.30 respectively for the same period of the previous year.
2019-10-14: Board Meeting
BEACONPHAR: Beacon Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on October 24, 2019 at 3.00 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2019.
2019-01-29: Un-audited HY A/Cs
BEACONPHAR: (Quarter 2) As per un-audited half yearly accounts of Beacon Pharmaceuticals Ltd., EPS was Tk. 0.19 for October-December 2018 as against Tk. 0.11 for October-December 2017; EPS was Tk. 0.35 for July-December 2018 as against Tk. 0.21 for July-December 2017. NOCFPS was Tk. 0.03 for July-December 2018 as against Tk. 1.00 for July-December 2017. NAV per share was Tk. 12.74 as on December 31, 2018 and Tk. 12.66 as on December 31, 2017.
2019-01-21: Board Meeting
BEACONPHAR: Beacon Pharmaceuticals Ltd. has informed that the Board Meeting of the Company will be held on January 28, 2019 at 3:30 PM to conside